All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00082239" target="_blank" >RIV/00216224:14740/15:00082239 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/15:00062984

  • Result on the web

    <a href="http://www.nature.com/leu/journal/vaop/ncurrent/pdf/leu2014196a.pdf" target="_blank" >http://www.nature.com/leu/journal/vaop/ncurrent/pdf/leu2014196a.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1038/leu.2014.196" target="_blank" >10.1038/leu.2014.196</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

  • Original language description

    Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 (n 1/4 3334), SF3B1 (n 1/4 2322), TP53 (n 1/4 2309), MYD88 (n 1/4 1080) and BIRC3 (n 1/4 919) genes,mainly at diagnosis (75%) and before treatment (490%). BIRC3 mutations (2.5%) were associated with unmutated IGHV genes (U-CLL), del(11q) and trisomy 12, whereas MYD88 mutations (2.2%) were exclusively found among M-CLL. NOTCH1, SF3B1 and TP53 exhibitedvariable frequencies and were mostly enriched within clinically aggressive cases. Interestingly, as the timespan between diagnosis and mutational screening increased, so too did the incidence of SF3B1 mutations; no such increase was observed for NOTCH1mutations. Regarding the clinical impact, NOTCH1 mutations, SF3B1 mutations and TP53 aberrations (deletion/mutation, TP53ab) correlated with shorter time-to-first-treatment (Po0.0001) in 889 treatment-naive Binet stage A cases.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Leukemia

  • ISSN

    0887-6924

  • e-ISSN

  • Volume of the periodical

    29

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    8

  • Pages from-to

    329-336

  • UT code for WoS article

    000349445000009

  • EID of the result in the Scopus database